JP2019513814A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513814A5 JP2019513814A5 JP2018555644A JP2018555644A JP2019513814A5 JP 2019513814 A5 JP2019513814 A5 JP 2019513814A5 JP 2018555644 A JP2018555644 A JP 2018555644A JP 2018555644 A JP2018555644 A JP 2018555644A JP 2019513814 A5 JP2019513814 A5 JP 2019513814A5
- Authority
- JP
- Japan
- Prior art keywords
- leucine
- acetyl
- acceptable salt
- pharmaceutically acceptable
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 18
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 claims 17
- 229960000669 acetylleucine Drugs 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 12
- 230000003920 cognitive function Effects 0.000 claims 6
- 230000004899 motility Effects 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 230000008447 perception Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021185130A JP7506046B2 (ja) | 2016-04-19 | 2021-11-12 | 改善される運動性及び認知機能のためのアセチル－ロイシン又はその薬学的に許容される塩 |
| JP2024096260A JP2024123087A (ja) | 2016-04-19 | 2024-06-13 | 改善される運動性及び認知機能のためのアセチル－ロイシン又はその薬学的に許容される塩 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201606834 | 2016-04-19 | ||
| GB1606834.8 | 2016-04-19 | ||
| PCT/GB2017/051090 WO2017182802A1 (en) | 2016-04-19 | 2017-04-19 | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021185130A Division JP7506046B2 (ja) | 2016-04-19 | 2021-11-12 | 改善される運動性及び認知機能のためのアセチル－ロイシン又はその薬学的に許容される塩 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2019513814A JP2019513814A (ja) | 2019-05-30 |
| JP2019513814A5 true JP2019513814A5 (enExample) | 2020-05-21 |
| JPWO2017182802A5 JPWO2017182802A5 (enExample) | 2022-01-21 |
| JP7387264B2 JP7387264B2 (ja) | 2023-11-28 |
Family
ID=58633040
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555644A Active JP7387264B2 (ja) | 2016-04-19 | 2017-04-19 | 改善される運動性及び認知機能のためのアセチル－ロイシン又はその薬学的に許容される塩 |
| JP2021185130A Active JP7506046B2 (ja) | 2016-04-19 | 2021-11-12 | 改善される運動性及び認知機能のためのアセチル－ロイシン又はその薬学的に許容される塩 |
| JP2024096260A Pending JP2024123087A (ja) | 2016-04-19 | 2024-06-13 | 改善される運動性及び認知機能のためのアセチル－ロイシン又はその薬学的に許容される塩 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021185130A Active JP7506046B2 (ja) | 2016-04-19 | 2021-11-12 | 改善される運動性及び認知機能のためのアセチル－ロイシン又はその薬学的に許容される塩 |
| JP2024096260A Pending JP2024123087A (ja) | 2016-04-19 | 2024-06-13 | 改善される運動性及び認知機能のためのアセチル－ロイシン又はその薬学的に許容される塩 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US10905670B2 (enExample) |
| EP (2) | EP4501406A3 (enExample) |
| JP (3) | JP7387264B2 (enExample) |
| KR (4) | KR102632670B1 (enExample) |
| CN (2) | CN118593463A (enExample) |
| AU (2) | AU2017252507B2 (enExample) |
| BR (1) | BR112018071547A2 (enExample) |
| CA (1) | CA3021155A1 (enExample) |
| DK (1) | DK3445351T3 (enExample) |
| ES (1) | ES2994242T3 (enExample) |
| FI (1) | FI3445351T3 (enExample) |
| HR (1) | HRP20241552T1 (enExample) |
| HU (1) | HUE069219T2 (enExample) |
| IL (3) | IL262379B (enExample) |
| LT (1) | LT3445351T (enExample) |
| MD (1) | MD3445351T2 (enExample) |
| MX (2) | MX388461B (enExample) |
| NZ (1) | NZ747307A (enExample) |
| PL (1) | PL3445351T3 (enExample) |
| PT (1) | PT3445351T (enExample) |
| RS (1) | RS66142B1 (enExample) |
| RU (1) | RU2745912C2 (enExample) |
| SG (2) | SG10202106190RA (enExample) |
| SI (1) | SI3445351T1 (enExample) |
| SM (1) | SMT202400459T1 (enExample) |
| WO (1) | WO2017182802A1 (enExample) |
| ZA (1) | ZA201806849B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4501406A3 (en) * | 2016-04-19 | 2025-03-26 | IntraBio Ltd | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
| LT3416631T (lt) | 2016-08-11 | 2019-08-26 | Intrabio Ltd | Terapiniai agentai, skirti neurodegeneracinių ligų gydymui |
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| CN113348018B (zh) | 2018-12-06 | 2025-04-01 | 内在生物技术有限公司 | 乙酰基-亮氨酸的氘代类似物 |
| IL321899A (en) * | 2019-03-02 | 2025-09-01 | Intrabio Ltd | Leucine, acetyl leucine and related analogs for the treatment of disease |
| WO2025019570A1 (en) * | 2023-07-18 | 2025-01-23 | Sytheon Ltd. | Novel amino acid based salts, compositions and methods for treating skin and rejuvenating skin and extending longevity |
| US12403111B2 (en) | 2024-02-02 | 2025-09-02 | SynGAP Research Fund | Compositions and methods for treating neurodevelopmental disorders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| FR2883180B1 (fr) * | 2005-03-18 | 2007-05-25 | Pierre Fabre Medicament Sa | Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre |
| FR2905600B1 (fr) * | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| US20080097606A1 (en) * | 2006-10-19 | 2008-04-24 | Cragg Andrew H | Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis |
| CA2687107A1 (en) * | 2007-05-08 | 2008-11-13 | Northern Innovations And Formulations Corp. | Branched-chain amino acid composition for improving skeletal muscle protein metabolism |
| US20120196257A1 (en) * | 2009-08-27 | 2012-08-02 | Joe Verghese | Cognitive function training to improve motor ability |
| TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| WO2012060844A1 (en) * | 2010-11-05 | 2012-05-10 | Biotie Therapies, Inc | A2a antagonists as cognition and motor function enhancers |
| TN2010000566A1 (en) * | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
| EP4501406A3 (en) * | 2016-04-19 | 2025-03-26 | IntraBio Ltd | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
| US12458614B2 (en) * | 2017-10-18 | 2025-11-04 | Intrabio Ltd | Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders |
-
2017
- 2017-04-19 EP EP24205813.9A patent/EP4501406A3/en active Pending
- 2017-04-19 SG SG10202106190RA patent/SG10202106190RA/en unknown
- 2017-04-19 SI SI201731566T patent/SI3445351T1/sl unknown
- 2017-04-19 KR KR1020227021015A patent/KR102632670B1/ko active Active
- 2017-04-19 HR HRP20241552TT patent/HRP20241552T1/hr unknown
- 2017-04-19 KR KR1020187032983A patent/KR20180134398A/ko not_active Ceased
- 2017-04-19 KR KR1020227008412A patent/KR102413754B1/ko active Active
- 2017-04-19 IL IL262379A patent/IL262379B/en unknown
- 2017-04-19 HU HUE17719692A patent/HUE069219T2/hu unknown
- 2017-04-19 LT LTEPPCT/GB2017/051090T patent/LT3445351T/lt unknown
- 2017-04-19 WO PCT/GB2017/051090 patent/WO2017182802A1/en not_active Ceased
- 2017-04-19 JP JP2018555644A patent/JP7387264B2/ja active Active
- 2017-04-19 IL IL293266A patent/IL293266B2/en unknown
- 2017-04-19 MD MDE20190248T patent/MD3445351T2/ro unknown
- 2017-04-19 CA CA3021155A patent/CA3021155A1/en active Pending
- 2017-04-19 RS RS20241222A patent/RS66142B1/sr unknown
- 2017-04-19 MX MX2018012739A patent/MX388461B/es unknown
- 2017-04-19 US US16/093,780 patent/US10905670B2/en active Active
- 2017-04-19 KR KR1020247003393A patent/KR102791288B1/ko active Active
- 2017-04-19 RU RU2018140131A patent/RU2745912C2/ru active
- 2017-04-19 NZ NZ747307A patent/NZ747307A/en unknown
- 2017-04-19 PL PL17719692.0T patent/PL3445351T3/pl unknown
- 2017-04-19 ES ES17719692T patent/ES2994242T3/es active Active
- 2017-04-19 BR BR112018071547-6A patent/BR112018071547A2/pt not_active Application Discontinuation
- 2017-04-19 DK DK17719692.0T patent/DK3445351T3/da active
- 2017-04-19 EP EP17719692.0A patent/EP3445351B1/en active Active
- 2017-04-19 IL IL310508A patent/IL310508A/en unknown
- 2017-04-19 SM SM20240459T patent/SMT202400459T1/it unknown
- 2017-04-19 CN CN202410876111.2A patent/CN118593463A/zh active Pending
- 2017-04-19 AU AU2017252507A patent/AU2017252507B2/en active Active
- 2017-04-19 SG SG11201809031XA patent/SG11201809031XA/en unknown
- 2017-04-19 PT PT177196920T patent/PT3445351T/pt unknown
- 2017-04-19 FI FIEP17719692.0T patent/FI3445351T3/fi active
- 2017-04-19 CN CN201780029480.6A patent/CN109069463B/zh active Active
-
2018
- 2018-10-15 ZA ZA2018/06849A patent/ZA201806849B/en unknown
- 2018-10-18 MX MX2021014844A patent/MX2021014844A/es unknown
-
2020
- 2020-12-22 US US17/247,757 patent/US11998518B2/en active Active
-
2021
- 2021-11-12 JP JP2021185130A patent/JP7506046B2/ja active Active
-
2022
- 2022-10-17 AU AU2022256077A patent/AU2022256077A1/en not_active Abandoned
-
2023
- 2023-07-10 US US18/349,221 patent/US12329733B2/en active Active
-
2024
- 2024-06-13 JP JP2024096260A patent/JP2024123087A/ja active Pending
-
2025
- 2025-05-13 US US19/206,473 patent/US20250332133A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513814A5 (enExample) | ||
| MX2021002321A (es) | Nuevos metodos. | |
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| WO2017083304A8 (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
| FI3936130T3 (fi) | Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon | |
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| CN110036005A (zh) | 酰胺衍生物及其在药物中的应用 | |
| WO2017070647A8 (en) | Nicotinamide for use in the treatment and prevention of ocular neurodegenerative disorder (e.g. glaucoma) | |
| JP2012193216A5 (enExample) | ||
| JP2018520189A5 (enExample) | ||
| JP2017506624A5 (enExample) | ||
| JP2015523407A5 (enExample) | ||
| JP2015522630A5 (enExample) | ||
| MX383665B (es) | Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. | |
| ZA202105976B (en) | Pharmaceutical dosage form for application to mucous membranes and methods for producing same | |
| HUE052332T2 (hu) | Heteroaril-származék vagy gyógyászatilag elfogadható sója, eljárás annak elõállítására, és az ezeket hatóanyagént tartalmazó gyógyászati készítmény PI3 kinázokkal összefüggõ betegségek megelõzésére vagy kezelésére | |
| RU2018140131A (ru) | Ацетил-лейцин или его фармацевтически приемлемая соль для улучшения двигательной функции и когнитивной функции | |
| MX2024015063A (es) | Leucina, acetilleucina y analogos relacionados para el tratamiento de enfermedades | |
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| IL273929B1 (en) | Therapeutic agents for neurodegenerative diseases | |
| HRP20211661T1 (hr) | Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti | |
| MY196333A (en) | Intranasal Composition Comprising Betahistine | |
| EP3639855A4 (en) | COMPOUNDS HAVING CASPASE INHIBITORING ACTIVITY, PHARMACEUTICAL AGENT CONTAINING THEM FOR THE TREATMENT OR PREVENTION OF SYMPTOMS, DISORDERS OR DISEASES OF CORNEAL ENDOTHELIUM, AND APPLICATION OF SUCH PHARMACEUTICAL AGENT | |
| IL277553A (en) | Preparations for the treatment of neurodegenerative diseases by continuous administration |